HoneyNaps Brings AI Sleep Tech to Boston's Kendall Square Hub

BOSTON, MA – April 28, 2026 – South Korean AI healthcare company HoneyNaps is making a significant strategic move into the heart of the world's premier biotechnology ecosystem, establishing a new presence in Boston's Kendall Square. The expansion, supported by a South Korean government initiative, positions the company to accelerate partnerships and vie for a larger share of the rapidly growing multi-billion dollar market for AI-driven sleep medicine.

HoneyNaps, which specializes in AI-powered sleep diagnostics, announced it will relocate its Boston operations to the Cambridge Innovation Center (CIC). The move is part of its selection for the Boston C&D Office Residency Program, an initiative under South Korea's 2026 Bio-health Global Expansion Support Program (K-VIP) designed to bolster the international competitiveness of the nation's most promising bio-health firms.

A Strategic Leap into the World's Biotech Hub

The decision to anchor its U.S. operations in Kendall Square is a calculated one. Often dubbed "the most innovative square mile on the planet," the Cambridge district is an unparalleled concentration of life science and technology power. It is home to over 250 biotech companies and serves as a major base for pharmaceutical giants such as Pfizer, Moderna, Novartis, and Eli Lilly and Company.

This dense ecosystem, anchored by world-class research institutions like the Massachusetts Institute of Technology (MIT) and the Broad Institute, creates a unique environment where groundbreaking research, clinical validation, commercialization, and venture capital converge. For a company like HoneyNaps, this proximity is invaluable, offering direct access to a deep talent pool and potential partners across the healthcare spectrum—from university labs to multinational pharmaceutical corporations seeking to optimize clinical trials. The Cambridge Innovation Center itself is a well-known launchpad for startups, fostering a culture of collaboration and providing a direct line to investors and industry leaders.

The Power of AI in Revolutionizing Sleep Medicine

The expansion comes as awareness of the critical link between sleep quality and overall health reaches an all-time high, fueling demand for more effective diagnostic tools. Traditionally, diagnosing sleep disorders like sleep apnea requires an overnight stay in a lab for a polysomnography (PSG) test, a cumbersome and costly process. The manual analysis of the resulting biosignal data can take a trained technician several hours.

HoneyNaps aims to disrupt this paradigm with its flagship AI software, SOMNUM. In a significant milestone, SOMNUM received U.S. Food and Drug Administration (FDA) 510(k) clearance in September 2023, making HoneyNaps the first Korean company to achieve this for an AI-based sleep biosignal analysis platform. The software uses deep learning algorithms to analyze complex data from EEGs, ECGs, and respiratory sensors in minutes, not hours.

A key feature is its use of Explainable AI (XAI), which provides clinicians with the rationale behind the AI's diagnostic conclusions, ensuring transparency and building trust. The technology's efficacy was validated in a peer-reviewed study published in Digital Health involving 1,000 adults. The results demonstrated SOMNUM's high accuracy, with a sensitivity of over 98% in detecting apnea and hypopnea events. This level of automation promises to reduce the time and cost associated with sleep studies by as much as 80-90%, a game-changing proposition for sleep centers and pharmaceutical companies conducting clinical trials for sleep-related therapies.

Riding a Wave of Market Growth and Government Support

HoneyNaps is entering the U.S. market at an opportune moment. The global market for AI in detecting sleep disorders, valued at nearly $1 billion in 2024, is projected to surge to $4.76 billion by 2033, growing at a compound annual rate of 19.2%. This growth is driven by an aging population, rising prevalence of sleep disorders, and a technological shift toward more accessible, data-driven healthcare solutions.

The company's expansion is further bolstered by the strong backing of the South Korean government. Its selection for the K-VIP program, administered by the Korea Health Industry Development Institute (KHIDI), signals a national strategic interest in fostering global champions in the bio-health sector. The program provides not just office space but also crucial market-entry support, networking, and strategic partnership development.

"We have been preparing for global expansion through our existing U.S. subsidiary in Boston and establishing a presence in Kendall Square marks an important next step in expanding both research collaborations and commercialization opportunities," stated Sean Ha, President of HoneyNaps USA, in a press release. "Being part of the same ecosystem as companies such as Pfizer, Moderna, Novartis, and Eli Lilly and Company will help us accelerate partnerships in sleep disorder clinical trials and strengthen our global market position."

Navigating a Crowded and Competitive Field

While the opportunity is vast, the competitive landscape is formidable. The sleep technology space is crowded with a diverse range of players. Established medical device manufacturers like ResMed and Philips dominate the sleep apnea therapy market, while consumer tech giants have made significant inroads with wearable devices. Apple recently received FDA clearance for a sleep apnea detection feature on its watch, and brands like Oura and Google's Fitbit have made sleep tracking a central feature of their wellness platforms.

HoneyNaps' strategy appears to be focused on carving out a distinct niche. Rather than competing directly with consumer wearables, its FDA-cleared SOMNUM software is positioned as a clinical-grade tool for healthcare providers and researchers. Its primary value proposition is not just tracking sleep, but providing rapid, accurate, and verifiable diagnostics that can integrate into clinical workflows and accelerate research. By establishing itself in Kendall Square, the company is betting that its clinically validated technology, combined with proximity to the industry's biggest players, will be the key to unlocking significant growth and securing its place as a leader in the next generation of digital sleep medicine.